Compare BCG & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BCG | IXHL |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8M | 45.0M |
| IPO Year | N/A | 2024 |
| Metric | BCG | IXHL |
|---|---|---|
| Price | $2.39 | $2.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 704.6K | 638.7K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.36 | $0.11 |
| 52 Week High | $3.44 | $6.39 |
| Indicator | BCG | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 46.96 |
| Support Level | $1.94 | $0.32 |
| Resistance Level | $2.53 | $3.68 |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | 0.04 | -0.17 |
| Stochastic Oscillator | 29.66 | 1.39 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.